Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

MLA

Cheng, Ann-Lii, et al. “Updated Efficacy and Safety Data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma.” Journal of Hepatology, vol. 76, no. 4, Apr. 2022, pp. 862–73. EBSCOhost, https://doi.org/10.1016/j.jhep.2021.11.030.

APA

Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., Li, D., Verret, W., Ma, N., Nicholas, A., Wang, Y., Li, L., Zhu, A. X., & Finn, R. S. (2022). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology, 76(4), 862–873. https://doi.org/10.1016/j.jhep.2021.11.030

Chicago

Cheng, Ann-Lii, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae-You Kim, Ho Yeong Lim, et al. 2022. “Updated Efficacy and Safety Data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma.” Journal of Hepatology 76 (4): 862–73. doi:10.1016/j.jhep.2021.11.030.